Included in the formulation
АТХ:G.03.G.A.02 Gonadotropin-menopausal
Pharmacodynamics:Human menopausal gonadotropin, containing follicle-stimulating hormone and luteinizing hormone in a ratio of 1: 1, has a gonadotropic effect. Increases the concentration of sex hormones in the blood plasma. In men, it induces spermatogenesis, affecting Sertoli cells. In women, before the pre-ovulatory stage, it stimulates the maturation of follicles in the ovaries, activates the proliferation of the endometrium, increasing the level of estrogens.
Pharmacokinetics:After intramuscular injection, the maximum concentration in the blood plasma is reached after 6-24 hours.
Metabolism in the liver.
The half-life is 4-12 hours. Elimination by the kidneys.
Indications:It is used for impaired fertility due to inadequate endogenous stimulation of gonads, for the treatment of female infertility as a result of anovulation, with disturbances in the maturation of the follicle with insufficient function of the yellow body.It is used for the purpose of controlled hyperstimulation for the purpose of assisted reproduction, in some cases in case of insufficiency of spermatogenesis.
IV.E20-E35.E23.0 Hypopituitarism
IV.E20-E35.E28.2 Polycystic ovary syndrome
IV.E20-E35.E29 Testicular dysfunction
XIV.N40-N51.N46 Male infertility
XIV.N80-N98.N97 Female infertility
XXI.Z30-Z39.Z31.1 Artificial insemination
Contraindications:Hyperprolactinemia, pancreas and kidney diseases, hypothalamic-pituitary tumors, polycystic ovaries, uterine bleeding of unexplained genesis, estrogen-dependent tumors of female genital organs, primary ovarian failure. For men: androgen-dependent tumors, prostate cancer, individual intolerance. Children under 18 years.
Carefully:Hypersensitivity.
Pregnancy and lactation:Recommendations for FDA - Category C. Contraindicated in pregnancy and lactation.
Dosing and Administration:Intramuscular, to treat infertility in women: mean initial dose: 75-150 IU follicle-stimulating hormonea + 75-150 IU luteinizing hormone per day. 1-2 days after the last injection, 5000-10000 IU of human chorionic gonadotropina.
Treatment of infertility in men: 75-150 IU follicle-stimulating hormonea + 75-150 IU luteinizing hormone per day in combination with 1000-3000 IU of human chorionic gonadotropina course for 3 months.
The highest daily dose: 150 IU.
The highest single dose: 150 IU.
Side effects:Digestive system: nausea, vomiting.
Musculoskeletal system: arthralgia.
Dermatological reactions: a rash.
Reproductive system: women - ovarian hyperstimulation syndrome: polycystic, hydrothorax, thromboembolism, ascites, oliguria, hypotension; multiple pregnancies; men - gynecomastia.
Allergic reactions.
Overdose:Increased side effects.
Treatment is symptomatic, drug cancellation.
Interaction:When used simultaneously with drugs that have activity luteinizing hormone, the risk of ovarian hyperstimulation syndrome increases.
Special instructions:Pregnancy following the induction of ovulation is associated with an increased risk of miscarriage and multiple pregnancy. During the treatment of women, the determination of estrogen levels, evaluation of ovarian size and ultrasound should be performed both before the start of therapy and regularly during the treatment.